KR102787188B1 - 방광암에 대한 신보조 요법 - Google Patents

방광암에 대한 신보조 요법 Download PDF

Info

Publication number
KR102787188B1
KR102787188B1 KR1020187020006A KR20187020006A KR102787188B1 KR 102787188 B1 KR102787188 B1 KR 102787188B1 KR 1020187020006 A KR1020187020006 A KR 1020187020006A KR 20187020006 A KR20187020006 A KR 20187020006A KR 102787188 B1 KR102787188 B1 KR 102787188B1
Authority
KR
South Korea
Prior art keywords
composition
neoadjuvant therapy
bladder
hal
bladder cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187020006A
Other languages
English (en)
Korean (ko)
Other versions
KR20180094987A (ko
Inventor
크제틸 헤스트달
Original Assignee
포토큐어 에이에스에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 포토큐어 에이에스에이 filed Critical 포토큐어 에이에스에이
Publication of KR20180094987A publication Critical patent/KR20180094987A/ko
Application granted granted Critical
Publication of KR102787188B1 publication Critical patent/KR102787188B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A61N5/0603—Apparatus for use inside the body for treatment of body cavities
    • A61N2005/061—Bladder and/or urethra
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0626—Monitoring, verifying, controlling systems and methods
    • A61N2005/0629—Sequential activation of light sources
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light
    • A61N2005/0663—Coloured light
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020187020006A 2015-12-17 2016-12-19 방광암에 대한 신보조 요법 Active KR102787188B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1522309.2 2015-12-17
GBGB1522309.2A GB201522309D0 (en) 2015-12-17 2015-12-17 Use
PCT/EP2016/081803 WO2017103283A1 (en) 2015-12-17 2016-12-19 Neoadjuvant therapy for bladder cancer

Publications (2)

Publication Number Publication Date
KR20180094987A KR20180094987A (ko) 2018-08-24
KR102787188B1 true KR102787188B1 (ko) 2025-03-25

Family

ID=55311159

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187020006A Active KR102787188B1 (ko) 2015-12-17 2016-12-19 방광암에 대한 신보조 요법

Country Status (14)

Country Link
US (2) US10556010B2 (enExample)
EP (1) EP3389717B9 (enExample)
JP (1) JP6926086B2 (enExample)
KR (1) KR102787188B1 (enExample)
CN (2) CN119345359A (enExample)
AU (1) AU2016372573B2 (enExample)
BR (1) BR112018012009B1 (enExample)
CA (1) CA3008551A1 (enExample)
DK (1) DK3389717T3 (enExample)
ES (1) ES3015668T3 (enExample)
FI (1) FI3389717T3 (enExample)
GB (1) GB201522309D0 (enExample)
PL (1) PL3389717T3 (enExample)
WO (1) WO2017103283A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522309D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use
GB201522311D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use
PH12020550124B1 (en) * 2017-12-01 2024-05-24 Nat Ct Child Health & Dev Pharmaceutical composition for enhancing antitumor effect by immune checkpoint inhibitor
KR102441358B1 (ko) 2020-09-14 2022-09-06 주식회사 아파트엔 아파트의 지수화를 통한 아파트 투자 가치 평가 시스템
AU2024231397A1 (en) 2023-03-07 2025-09-25 Photocure Asa Therapy for bladder cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ291132B6 (cs) 1995-03-10 2002-12-11 Photocure Asa Estery kyselin 5-aminolevulových a farmaceutický prostředek s jejich obsahem
US7530461B2 (en) * 1995-03-10 2009-05-12 Photocure Asa Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
GB0018528D0 (en) * 2000-07-27 2000-09-13 Photocure Asa Compounds
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
GB0406917D0 (en) 2004-03-26 2004-04-28 Photocure Asa Compounds
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
KR101411165B1 (ko) 2005-07-01 2014-06-25 메다렉스, 엘.엘.시. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
WO2010077634A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
CN102458388B (zh) 2009-06-11 2016-09-28 光治疗Asa公司 半固体组合物及药物制品
AR087405A1 (es) 2011-08-01 2014-03-19 Genentech Inc Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek
EP2785375B1 (en) 2011-11-28 2020-07-22 Merck Patent GmbH Anti-pd-l1 antibodies and uses thereof
EP2855528B1 (en) 2012-05-31 2019-06-19 Genentech, Inc. Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
US8927761B2 (en) 2012-06-28 2015-01-06 Photocure Asa Form of hexyl-5-aminolevulinate hydrochloride and methods of using the same
WO2014020164A1 (en) * 2012-08-03 2014-02-06 Photocure Asa Compounds
GB201522309D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use
CN109010850B (zh) * 2018-08-01 2021-10-22 上海师范大学 一种负载姜黄素的葡聚糖修饰的钆掺杂的空心介孔二氧化硅纳米材料的制备方法及应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
M. J. Bader et al., Urologic Oncology: Seminars and Original Investigations 31 (2013) 1178-1183.*
S. Sundararajan et al., Future Oncology, 2015, 11(16), 2299-2306.

Also Published As

Publication number Publication date
CN119345359A (zh) 2025-01-24
GB201522309D0 (en) 2016-02-03
EP3389717A1 (en) 2018-10-24
JP2018537514A (ja) 2018-12-20
AU2016372573B2 (en) 2022-07-21
DK3389717T3 (da) 2025-03-31
US20200155683A1 (en) 2020-05-21
US11311620B2 (en) 2022-04-26
JP6926086B2 (ja) 2021-08-25
PL3389717T3 (pl) 2025-06-09
CN108601836A (zh) 2018-09-28
US20180369379A1 (en) 2018-12-27
BR112018012009B1 (pt) 2023-12-19
AU2016372573A1 (en) 2018-07-12
BR112018012009A2 (pt) 2018-12-04
RU2018124868A3 (enExample) 2020-05-13
FI3389717T3 (fi) 2025-04-08
EP3389717B9 (en) 2025-07-23
ES3015668T3 (en) 2025-05-07
WO2017103283A1 (en) 2017-06-22
EP3389717B1 (en) 2025-02-19
US10556010B2 (en) 2020-02-11
KR20180094987A (ko) 2018-08-24
RU2018124868A (ru) 2020-01-27
CA3008551A1 (en) 2017-06-22

Similar Documents

Publication Publication Date Title
US11311620B2 (en) Neoadjuvant therapy for bladder cancer
US11066478B2 (en) Intravesical therapy for bladder cancer
US20220152411A1 (en) Method of photodynamic therapy (pdt) for bladder cancer
RU2783177C2 (ru) Неоадъювантная терапия для рака мочевого пузыря
RU2779543C2 (ru) Внутрипузырная терапия для рака мочевого пузыря
KR20250154511A (ko) 방광암 치료

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180712

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211220

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231214

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20241223

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250321

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250321

End annual number: 3

Start annual number: 1

PG1601 Publication of registration